<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg"/></p>
<p>TransMedics 集團股票（NASDAQ：TMDX）在發佈 2023 年第三季度財報後經歷了顯著的股價下跌。公司股價暴跌超過 25％，這一反應被歸因於低於預期的營收和利潤數據。</p>
<p>以其創新器官移植技術而聞名的 TransMedics 報告稱，該季度營收為 4200 萬美元，低於分析師對 4500 萬美元的預期。該季度淨虧損為 750 萬美元，而去年同期淨收入為 200 萬美元。財務表現的 drastical 變化引發了投資者對公司未來增長軌跡和盈利能力的擔憂。</p>
<p>導致營收不及預期的關鍵因素之一是 TransMedics 的器官護理系統（OCS）技術的採用速度低於預期。儘管 OCS 被譽為器官保存和移植的開創性解決方案，但其融入臨牀實踐面臨了諸多障礙，包括監管挑戰和來自傳統保存方法的競爭。</p>
<p>此外，公司的運營成本激增，主要是由於加大了用於推廣 OCS 技術的研發和營銷支出。這些支出給公司的底線帶來了額外壓力，加劇了營收不及預期的影響。</p>
<p>TransMedics 首席執行官 Waleed Hassanein 博士在財報電話會議中回應了這些擔憂，強調了公司的長期願景和克服當前障礙的承諾。他強調了擴大全球使用 OCS 技術的持續舉措，並向投資者保證公司致力於在關鍵市場獲得監管批准。</p>
<p>儘管存在即時的財務挫折，一些分析師對 TransMedics 未來前景持樂觀態度。他們指出器官移植需求增長以及 OCS 技術革新該領域的潛力作為可能推動公司長期成功的因素。然而，他們也警告稱，通往廣泛採用和盈利的道路可能比最初預期的更漫長和更具挑戰性。</p>
<p>總之，TransMedics 股價最近的暴跌凸顯了生物技術行業的波動性，公司往往面臨重大的財務和運營挑戰。儘管公司的創新技術具有潛力，但其在規管環境中航行並實現商業成功的能力將對其未來表現至關重要。</p>
<p><strong>腳註：</strong></p>
<p>特色圖片：DepositPhotos @ Capifrutta</p>
<p>免責聲明</p>
<p>本文轉載自 Invezz</p>

TMDX

<p>TransMedics 集團公司（NASDAQ：TMDX）發佈了 2023 年第三季度財報，營收和利潤均未達到預期，導致股價下跌超過 25%。公司報告的營收顯著低於分析師預測，並出現了與去年相比的淨虧損。器官護理系統的採用挑戰和運營成本上升導致了這一下滑。儘管引發了一些擔憂，但一些分析師仍對未來增長持樂觀態度，因為器官移植需求不斷增加</p>

<p><img src="https://imageproxy.pbkrs.com/https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg" alt="" original-src="https://ik.imagekit.io/invezz/uploads/2024/09/aa35c3157b628a248aaf3d8225487158.jpg"/></p>
<p>TransMedics Group Inc. (NASDAQ:TMDX) experienced a significant drop in its stock price following the release of its Q3 2023 earnings report. The company’s stock plummeted by over 25%, a reaction attributed to the lower-than-expected revenue and profit figures.</p>
<div class="lb-trans"><p>TransMedics 集團股票（NASDAQ：TMDX）在發佈 2023 年第三季度財報後經歷了顯著的股價下跌。公司股價暴跌超過 25％，這一反應被歸因於低於預期的營收和利潤數據。</p>
</div><p>TransMedics, renowned for its innovative organ transplant technologies, reported revenues of $42 million for the quarter, which fell short of analysts’ expectations of $45 million. The net loss for the quarter was reported at $7.5 million, compared to a net income of $2 million in the same period last year. This drastic change in financial performance raised concerns among investors about the company’s growth trajectory and profitability in the near future.</p>
<div class="lb-trans"><p>以其創新器官移植技術而聞名的 TransMedics 報告稱，該季度營收為 4200 萬美元，低於分析師對 4500 萬美元的預期。該季度淨虧損為 750 萬美元，而去年同期淨收入為 200 萬美元。財務表現的 drastical 變化引發了投資者對公司未來增長軌跡和盈利能力的擔憂。</p>
</div><p>One of the key factors contributing to the revenue shortfall was the slower-than-anticipated adoption of TransMedics’ Organ Care System (OCS) technology. While the OCS has been touted as a groundbreaking solution for organ preservation and transplantation, its integration into clinical practice has faced several hurdles, including regulatory challenges and competition from established preservation methods.</p>
<div class="lb-trans"><p>導致營收不及預期的關鍵因素之一是 TransMedics 的器官護理系統（OCS）技術的採用速度低於預期。儘管 OCS 被譽為器官保存和移植的開創性解決方案，但其融入臨牀實踐面臨了諸多障礙，包括監管挑戰和來自傳統保存方法的競爭。</p>
</div><p>Furthermore, the company’s operational costs have surged, primarily due to increased spending on research and development (R&amp;D) and marketing efforts aimed at promoting the OCS technology. These expenses have put additional pressure on the company’s bottom line, exacerbating the impact of the revenue miss.</p>
<div class="lb-trans"><p>此外，公司的運營成本激增，主要是由於加大了用於推廣 OCS 技術的研發和營銷支出。這些支出給公司的底線帶來了額外壓力，加劇了營收不及預期的影響。</p>
</div><p>TransMedics’ CEO, Dr. Waleed Hassanein, addressed these concerns during the earnings call, emphasizing the company’s long-term vision and commitment to overcoming the current obstacles. He highlighted ongoing initiatives to expand the use of OCS technology globally and assured investors of the company’s dedication to achieving regulatory approvals in key markets.</p>
<div class="lb-trans"><p>TransMedics 首席執行官 Waleed Hassanein 博士在財報電話會議中回應了這些擔憂，強調了公司的長期願景和克服當前障礙的承諾。他強調了擴大全球使用 OCS 技術的持續舉措，並向投資者保證公司致力於在關鍵市場獲得監管批准。</p>
</div><p>Despite the immediate financial setbacks, some analysts remain optimistic about TransMedics’ future prospects. They point to the growing demand for organ transplants and the potential for OCS technology to revolutionize the field as factors that could drive the company’s success in the long run. However, they also caution that the path to widespread adoption and profitability may be longer and more challenging than initially anticipated.</p>
<div class="lb-trans"><p>儘管存在即時的財務挫折，一些分析師對 TransMedics 未來前景持樂觀態度。他們指出器官移植需求增長以及 OCS 技術革新該領域的潛力作為可能推動公司長期成功的因素。然而，他們也警告稱，通往廣泛採用和盈利的道路可能比最初預期的更漫長和更具挑戰性。</p>
</div><p>In conclusion, the recent plunge in TransMedics’ stock price underscores the volatile nature of the biotech sector, where companies often face significant financial and operational challenges. While the company’s innovative technology holds promise, its ability to navigate regulatory landscapes and achieve commercial success will be crucial in determining its future performance.</p>
<div class="lb-trans"><p>總之，TransMedics 股價最近的暴跌凸顯了生物技術行業的波動性，公司往往面臨重大的財務和運營挑戰。儘管公司的創新技術具有潛力，但其在規管環境中航行並實現商業成功的能力將對其未來表現至關重要。</p>
</div><p><strong>Footnotes:</strong></p>
<div class="lb-trans"><p><strong>腳註：</strong></p>
</div><p>Featured Image: DepositPhotos @ Capifrutta</p>
<div class="lb-trans"><p>特色圖片：DepositPhotos @ Capifrutta</p>
</div><p>Disclaimer</p>
<div class="lb-trans"><p>免責聲明</p>
</div><p>The post TransMedics Stock Plunges Post-Q3 Results appeared first on Invezz</p>
<div class="lb-trans"><p>本文轉載自 Invezz</p>
</div>

TransMedics 股票在第三季度業績公佈後大幅下跌